Julie Christine Lauffenburger, Ph.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medication Adherence | 32 | 2024 | 2190 | 4.490 |
Why?
|
Prescription Drugs | 5 | 2023 | 634 | 1.660 |
Why?
|
Inappropriate Prescribing | 4 | 2024 | 212 | 1.640 |
Why?
|
Pharmaceutical Services | 6 | 2021 | 145 | 1.510 |
Why?
|
Pharmacy | 2 | 2022 | 92 | 1.390 |
Why?
|
Hypoglycemic Agents | 10 | 2024 | 3108 | 1.330 |
Why?
|
Hypertension | 16 | 2024 | 8616 | 1.310 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2023 | 347 | 1.280 |
Why?
|
Chronic Disease | 11 | 2021 | 9357 | 1.060 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2023 | 12245 | 0.880 |
Why?
|
Health Expenditures | 6 | 2023 | 2390 | 0.860 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2024 | 427 | 0.780 |
Why?
|
Electronic Prescribing | 1 | 2021 | 115 | 0.700 |
Why?
|
Touch Perception | 1 | 2021 | 106 | 0.700 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2030 | 0.680 |
Why?
|
Pharmacies | 2 | 2021 | 171 | 0.670 |
Why?
|
Pharmacists | 4 | 2019 | 261 | 0.660 |
Why?
|
Reinforcement, Social | 1 | 2018 | 11 | 0.640 |
Why?
|
Gout | 2 | 2023 | 622 | 0.620 |
Why?
|
Anticoagulants | 6 | 2024 | 4855 | 0.620 |
Why?
|
Cardiovascular Agents | 3 | 2019 | 849 | 0.600 |
Why?
|
Medicare | 12 | 2024 | 6820 | 0.590 |
Why?
|
Nurse Practitioners | 1 | 2021 | 270 | 0.580 |
Why?
|
Glycemic Index | 1 | 2020 | 400 | 0.560 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1445 | 0.540 |
Why?
|
Uric Acid | 1 | 2023 | 809 | 0.540 |
Why?
|
United States | 33 | 2024 | 72951 | 0.530 |
Why?
|
Warfarin | 3 | 2024 | 1494 | 0.530 |
Why?
|
Cardiovascular Diseases | 7 | 2023 | 15657 | 0.520 |
Why?
|
Insulin | 3 | 2020 | 6608 | 0.520 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 3250 | 0.520 |
Why?
|
Retrospective Studies | 29 | 2024 | 81635 | 0.510 |
Why?
|
Drug Prescriptions | 3 | 2024 | 1663 | 0.510 |
Why?
|
Metformin | 1 | 2023 | 908 | 0.510 |
Why?
|
Complementary Therapies | 1 | 2020 | 486 | 0.510 |
Why?
|
Health Care Costs | 2 | 2020 | 3242 | 0.500 |
Why?
|
Fee-for-Service Plans | 1 | 2020 | 713 | 0.490 |
Why?
|
Medical Informatics | 1 | 2022 | 744 | 0.490 |
Why?
|
Medication Therapy Management | 2 | 2017 | 131 | 0.490 |
Why?
|
Community Pharmacy Services | 2 | 2012 | 52 | 0.480 |
Why?
|
Atrial Fibrillation | 5 | 2024 | 5182 | 0.480 |
Why?
|
Vaccines | 1 | 2023 | 842 | 0.480 |
Why?
|
Humans | 83 | 2024 | 766766 | 0.460 |
Why?
|
Communication | 4 | 2022 | 3905 | 0.460 |
Why?
|
Cost Control | 1 | 2017 | 628 | 0.460 |
Why?
|
Health Services Needs and Demand | 1 | 2022 | 1404 | 0.460 |
Why?
|
Shock, Septic | 1 | 2020 | 772 | 0.450 |
Why?
|
Female | 55 | 2024 | 396520 | 0.440 |
Why?
|
Diabetes Complications | 1 | 2020 | 1319 | 0.430 |
Why?
|
Medicare Part D | 2 | 2019 | 355 | 0.430 |
Why?
|
Primary Health Care | 6 | 2024 | 4735 | 0.410 |
Why?
|
Aged | 35 | 2024 | 171343 | 0.400 |
Why?
|
Male | 47 | 2024 | 364142 | 0.400 |
Why?
|
Polypharmacy | 3 | 2021 | 307 | 0.390 |
Why?
|
Social Support | 1 | 2022 | 2191 | 0.390 |
Why?
|
Antidepressive Agents | 1 | 2024 | 2903 | 0.380 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1885 | 0.380 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3837 | 0.380 |
Why?
|
Diabetes Mellitus | 7 | 2021 | 5887 | 0.380 |
Why?
|
Life Change Events | 1 | 2016 | 956 | 0.370 |
Why?
|
Middle Aged | 33 | 2024 | 223257 | 0.360 |
Why?
|
Formularies as Topic | 1 | 2011 | 93 | 0.360 |
Why?
|
Databases, Factual | 4 | 2016 | 8066 | 0.350 |
Why?
|
Electronic Health Records | 4 | 2024 | 4880 | 0.340 |
Why?
|
Prescriptions | 2 | 2023 | 388 | 0.340 |
Why?
|
Self Report | 4 | 2023 | 3771 | 0.340 |
Why?
|
Hyperlipidemias | 4 | 2018 | 771 | 0.330 |
Why?
|
Pharmacoepidemiology | 1 | 2013 | 351 | 0.330 |
Why?
|
Patient Participation | 2 | 2024 | 1445 | 0.330 |
Why?
|
Patient Compliance | 1 | 2019 | 2694 | 0.310 |
Why?
|
Drugs, Generic | 1 | 2013 | 457 | 0.290 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2015 | 1126 | 0.290 |
Why?
|
Family | 1 | 2018 | 3209 | 0.290 |
Why?
|
Telephone | 2 | 2022 | 629 | 0.280 |
Why?
|
Heart Failure | 4 | 2024 | 11882 | 0.270 |
Why?
|
Sepsis | 1 | 2020 | 2604 | 0.270 |
Why?
|
Health Behavior | 1 | 2018 | 2649 | 0.270 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1033 | 0.260 |
Why?
|
Telemedicine | 2 | 2021 | 3111 | 0.260 |
Why?
|
Decision Making | 2 | 2022 | 3951 | 0.260 |
Why?
|
Thrombolytic Therapy | 1 | 2015 | 2053 | 0.250 |
Why?
|
Insurance Claim Review | 3 | 2020 | 744 | 0.250 |
Why?
|
Internship and Residency | 2 | 2024 | 5943 | 0.250 |
Why?
|
Drug Costs | 2 | 2023 | 1195 | 0.250 |
Why?
|
Long-Term Care | 2 | 2020 | 630 | 0.240 |
Why?
|
Blood Pressure | 6 | 2023 | 8533 | 0.240 |
Why?
|
Aged, 80 and over | 12 | 2024 | 59550 | 0.230 |
Why?
|
Insurance, Health | 1 | 2017 | 2520 | 0.230 |
Why?
|
Adult | 24 | 2024 | 223307 | 0.230 |
Why?
|
Physicians | 1 | 2022 | 4591 | 0.230 |
Why?
|
Cholinergic Antagonists | 1 | 2024 | 165 | 0.210 |
Why?
|
Atherosclerosis | 3 | 2023 | 3420 | 0.200 |
Why?
|
Cohort Studies | 9 | 2023 | 41710 | 0.200 |
Why?
|
Administration, Oral | 4 | 2024 | 4018 | 0.200 |
Why?
|
Antiviral Agents | 1 | 2014 | 3070 | 0.190 |
Why?
|
Brain Ischemia | 1 | 2015 | 3001 | 0.190 |
Why?
|
Risk Assessment | 5 | 2024 | 24295 | 0.190 |
Why?
|
Blood Pressure Determination | 2 | 2022 | 646 | 0.190 |
Why?
|
Patient Care | 2 | 2020 | 629 | 0.180 |
Why?
|
Gout Suppressants | 1 | 2023 | 176 | 0.180 |
Why?
|
Tranexamic Acid | 1 | 2023 | 174 | 0.180 |
Why?
|
Qualitative Research | 2 | 2022 | 3138 | 0.180 |
Why?
|
Antifibrinolytic Agents | 1 | 2023 | 289 | 0.170 |
Why?
|
Blood Glucose | 3 | 2020 | 6422 | 0.170 |
Why?
|
Electronics | 1 | 2021 | 315 | 0.170 |
Why?
|
Medical Staff, Hospital | 1 | 2024 | 602 | 0.170 |
Why?
|
Insurance Carriers | 1 | 2021 | 159 | 0.160 |
Why?
|
Logistic Models | 4 | 2019 | 13278 | 0.160 |
Why?
|
New Jersey | 1 | 2020 | 296 | 0.160 |
Why?
|
Behavior Control | 1 | 2019 | 46 | 0.160 |
Why?
|
Vaccination | 2 | 2023 | 3434 | 0.160 |
Why?
|
Myocardial Infarction | 3 | 2015 | 11513 | 0.160 |
Why?
|
Technology | 1 | 2021 | 296 | 0.160 |
Why?
|
Postal Service | 1 | 2018 | 96 | 0.150 |
Why?
|
Drugs, Investigational | 2 | 2018 | 211 | 0.150 |
Why?
|
Medicare Part B | 1 | 2019 | 116 | 0.150 |
Why?
|
Benzodiazepines | 1 | 2024 | 1137 | 0.150 |
Why?
|
Public Health | 1 | 2011 | 2681 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2024 | 1469 | 0.140 |
Why?
|
Sex Factors | 3 | 2024 | 10619 | 0.140 |
Why?
|
Remote Consultation | 1 | 2020 | 241 | 0.140 |
Why?
|
Frail Elderly | 1 | 2023 | 781 | 0.140 |
Why?
|
Policy | 1 | 2021 | 512 | 0.140 |
Why?
|
Adenosine Diphosphate | 1 | 2018 | 421 | 0.140 |
Why?
|
Risk Factors | 9 | 2023 | 74881 | 0.140 |
Why?
|
Hypnotics and Sedatives | 1 | 2024 | 1193 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1208 | 0.120 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 1065 | 0.120 |
Why?
|
Cost Sharing | 1 | 2019 | 409 | 0.120 |
Why?
|
Reminder Systems | 1 | 2018 | 389 | 0.120 |
Why?
|
Biotransformation | 1 | 2014 | 165 | 0.120 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26310 | 0.120 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2014 | 117 | 0.110 |
Why?
|
Comorbidity | 3 | 2020 | 10580 | 0.110 |
Why?
|
Small-Area Analysis | 1 | 2014 | 51 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10384 | 0.110 |
Why?
|
Age Factors | 4 | 2024 | 18397 | 0.110 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39309 | 0.110 |
Why?
|
Drug Approval | 2 | 2018 | 820 | 0.110 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
Education, Pharmacy | 1 | 2012 | 38 | 0.100 |
Why?
|
Prevalence | 3 | 2021 | 15835 | 0.100 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 878 | 0.100 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1514 | 0.100 |
Why?
|
Referral and Consultation | 2 | 2022 | 3618 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2017 | 904 | 0.100 |
Why?
|
Income | 1 | 2020 | 1875 | 0.090 |
Why?
|
Odds Ratio | 1 | 2024 | 9661 | 0.090 |
Why?
|
International Normalized Ratio | 1 | 2013 | 382 | 0.090 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2024 | 2763 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2662 | 0.090 |
Why?
|
Regression Analysis | 2 | 2018 | 6329 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2659 | 0.090 |
Why?
|
Propensity Score | 2 | 2015 | 1972 | 0.090 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2108 | 0.080 |
Why?
|
Malawi | 1 | 2011 | 312 | 0.080 |
Why?
|
Drug Interactions | 1 | 2014 | 1419 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2021 | 1880 | 0.080 |
Why?
|
Research Design | 3 | 2021 | 6207 | 0.080 |
Why?
|
Publishing | 1 | 2016 | 837 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7841 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2274 | 0.080 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 713 | 0.080 |
Why?
|
Cesarean Section | 1 | 2017 | 1418 | 0.080 |
Why?
|
Public Policy | 1 | 2012 | 551 | 0.070 |
Why?
|
Survival Analysis | 1 | 2020 | 10100 | 0.070 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1241 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2869 | 0.070 |
Why?
|
Registries | 1 | 2024 | 8351 | 0.070 |
Why?
|
Drug Utilization | 1 | 2013 | 1187 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5536 | 0.070 |
Why?
|
Influenza, Human | 1 | 2018 | 1543 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2006 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3799 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2024 | 65273 | 0.070 |
Why?
|
Prognosis | 2 | 2020 | 29948 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2013 | 962 | 0.070 |
Why?
|
Hypolipidemic Agents | 2 | 2024 | 609 | 0.070 |
Why?
|
Health Personnel | 1 | 2021 | 3384 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3432 | 0.070 |
Why?
|
Pain, Postoperative | 1 | 2017 | 1768 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6307 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 418 | 0.070 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 791 | 0.070 |
Why?
|
Young Adult | 4 | 2021 | 59939 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5368 | 0.070 |
Why?
|
Reimbursement Mechanisms | 1 | 2012 | 670 | 0.070 |
Why?
|
Focus Groups | 1 | 2012 | 1459 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14652 | 0.060 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 3692 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8540 | 0.060 |
Why?
|
Adolescent | 4 | 2021 | 88904 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2188 | 0.060 |
Why?
|
Transcription Factors | 1 | 2024 | 12150 | 0.060 |
Why?
|
Osteoporosis | 1 | 2013 | 1581 | 0.060 |
Why?
|
Hospitalization | 1 | 2024 | 10823 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2116 | 0.060 |
Why?
|
Disease Progression | 1 | 2020 | 13640 | 0.050 |
Why?
|
Linear Models | 1 | 2013 | 5874 | 0.050 |
Why?
|
Hemoptysis | 1 | 2023 | 152 | 0.050 |
Why?
|
Denmark | 1 | 2024 | 777 | 0.050 |
Why?
|
Digoxin | 1 | 2022 | 246 | 0.050 |
Why?
|
Time Factors | 2 | 2024 | 40149 | 0.050 |
Why?
|
Habits | 1 | 2021 | 148 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2012 | 2779 | 0.040 |
Why?
|
Administration, Inhalation | 1 | 2023 | 1154 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14762 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2023 | 374 | 0.040 |
Why?
|
Pyridones | 1 | 2024 | 818 | 0.040 |
Why?
|
Behavioral Sciences | 1 | 2018 | 28 | 0.040 |
Why?
|
Stroke | 2 | 2024 | 9741 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2022 | 1026 | 0.030 |
Why?
|
Thiazoles | 1 | 2024 | 1529 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2012 | 4306 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2016 | 70 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 2 | 2022 | 3230 | 0.030 |
Why?
|
Tetrazoles | 1 | 2022 | 923 | 0.030 |
Why?
|
Deductibles and Coinsurance | 1 | 2018 | 315 | 0.030 |
Why?
|
Drug Combinations | 1 | 2022 | 2085 | 0.030 |
Why?
|
Immunization Programs | 1 | 2018 | 267 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13643 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 499 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2030 | 0.030 |
Why?
|
Students, Pharmacy | 1 | 2012 | 17 | 0.030 |
Why?
|
Pyridines | 1 | 2024 | 2888 | 0.030 |
Why?
|
Safety | 1 | 2016 | 1157 | 0.020 |
Why?
|
Injections | 1 | 2013 | 839 | 0.020 |
Why?
|
Obstetrics | 1 | 2017 | 679 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4056 | 0.020 |
Why?
|
Professional Role | 1 | 2012 | 314 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 2007 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1673 | 0.020 |
Why?
|
Faculty | 1 | 2012 | 383 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 22350 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3411 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5618 | 0.020 |
Why?
|
Advisory Committees | 1 | 2012 | 797 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4252 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9602 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2836 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1463 | 0.020 |
Why?
|
Teaching | 1 | 2012 | 1171 | 0.010 |
Why?
|
Exercise | 1 | 2019 | 5945 | 0.010 |
Why?
|
Prospective Studies | 2 | 2018 | 54871 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 30237 | 0.010 |
Why?
|